INDUSTRY SYMPOSIUM 6

 

13:15 - 15:15   G106-107

 

A New Frontier in CKD Anemia Understanding: the interlinking roles of Inflammation, FGF-23, and Oral Iron
 
Chairs: David Goldsmith, London, UK
Christoph Wanner, Würzburg, Germany

A Silent Killer - The Role of IV Iron in Inflammation in Kidney Disease
Peter Stenvinkel, Stockholm, Sweden
 
Emerging CKD Clinical Markers - a Discussion of FGF-23 and Iron
Myles S. Wolf, Chicago, USA
 
The role of Oral Iron in the Optimization of Anaemia Management in CKD
Steve Fishbane, New York, USA
 
Panel Discussion

Organised by KERYX BIOPHARMACEUTICALS 

 

back to the timetable